

# Statistics on R&D Activities 2009



Identification of the	organisation or centre		
Amandments to the ide	entification portioulars /C		-4:
Amendments to the ide	entification particulars (Cor	npiete only those se	ctions subject to variation)
Name of the organisation or centre			NIF
Registered address (street, square, avenue, et	c.)		
Postal code Municipality			
Province	Provincial code Telephone	Fax	E-mail
Details of the person to be con queries, clarifications or modif	ntacted, if necessary, for ications regarding this questionn	aire.	SIGNATURE OR SEAL
Mr./Ms.:			
Post held:			
Telephone	Fax:		
E-mail:			
Website:			

# Nature, characteristics and purpose

These statistics are within the framework of the General plan for statistics on science and technology promoted by the Statistics Office of the European Union (Eurostat). They have the main objective of ascertaining the resources that research organisations and centres spend on R&D, for the purpose of estimating the national effort in research.

They are conducted following recommendations of the OECD (Frascati Manual).

# Statistical Legislation of compulsory compliance

# Statistical Secrecy

The personal information obtained by the statistical services, both directly from the informants and from administrative sources, shall be subject to protection, and covered by **statistical secrecy** (article 13.1 of the Law on Public Statistical Services, of 9 May 1989, (LFEP)). All statistical staff will be obliged to maintain statistical secrecy (article 17.1 of the LFEP).

# Obligation to provide data

Laws 4/1990 and 13/1996 establish the obligation to provide the data that is requested for the compilation of these Statistics.

The statistical services may request data from all individuals and companies, regardless of whether they are Spanish or foreign, resident in Spain (Article 10.1 of the LFEP).

All individuals and legal entities that provide data, regardless of whether their collaboration is compulsory or voluntary, must respond in a true, exact and comprehensive manner within the stipulated deadline to the questions outlined in due form by the statistical services (art. 10.2 of the LFEP).

In order to monitor compliance with these regulation, the LFEP (art. 48) grants the INE sanctioning capacity.

Failure to comply with the obligations envisaged in this Law, as related to statistics for state purposes, shall be sanctioned in accordance with the terms established in the regulations contained in this Heading (art. 48.1 of the LFEP).

Very serious infringements shall be sanctioned with fines ranging from 3,005.07 to 30,050.61 euros. Serious infringements shall be sanctioned with fines ranging from 300.52 to 3,005.06 euros. Minor infringements shall be sanctioned with fines ranging from 60.10 to 300.51 euros (art. 51.1, 51.2 and 51.3 of the LFEP).

# General considerations

For the purposes of these statistics, the following are regarded as R&D activities: the group of creative activities undertaken systematically, in order to increase the flow of scientific and technical knowledge and use them to introduce new applications. This activity comprises basic research, applied research and experimental development. The latter leads to new devices, products, materials, processes, services or systems.

The following are not included as R&D activities: education, scientific and technical information, collection of data of a general nature, routine trials, everyday standardisation work or other technological activities relating to production or use of known products or processes. Mineral exploration is not included either, when it is aimed at discovering exploitable reserves and not essentially an increase in basic geological knowledge.

The criterion distinguishing R&D from other activities is the presence or lack of a notable degree of creativity or innovation.

# General instructions

Information unit: The information that is requested in this questionnaire refers to the unit, organisation or centre whose identification data appears on the front cover. The data requested refers to all of the units dependent on this.

Reference period: Data must refer to the target year of the statistics.

Form of recording the data: Write down the data clearly. Please do not write in the shaded areas. The financial data is requested in euros with no decimals.

Consignment term: This questionnaire, duly completed with the required information, must be returned within a term not exceeding 15 days from

Please carefully read the annex before completing this questionnaire.

1. General data for the organisation o	or centre
--	-----------

1.1 List of centres whose research data is included in this questionnaire	
Please enter the name, Tax Identification Number (NIF) and full address	
1	
23	
4	
5	
6	
8	
9	
1.2 Type of administration on which it depends	
Please mark where appropriate with an 'X':	
State Administration	5
Autonomous Administration	6
Local Administration (Regional Council, Municipal Council and the like)	7
PNPI* mainly controlled and/or financed by the Administration	8
(*) PNPI: Private Non-Profit Institutions.	
1.3 Institution type	
Please mark where appropriate with an 'X':	
Administrative service (of a ministry, department, regional council, municipal council, etc.)	1
Administrative autonomous organisation	2
Trade, industrial, financial or similar autonomous organisation	3
Other public law entity Specify:	4
1.4 Administrative unit immediately above, to which it responds	
Please write the full name of the administrative unit immediately above	
1.5 Functional dependency of health establishments	
Only answer this question where the research body or centre identified on the cover of the questionna (hospital, clinic, sanatorium, hospital complex, etc.). Please mark the dependency of the centre with an	
National Health Management Institute	1
Health Service of the Autonomous Community	2
Regional or Municipal Council (including Insular Council, Inter-island Council and the like)	3
Other State Administration and Social Security units	4
Other Autonomous Administration units	5
Another entity (Please specify: other jointly-managed public bodies, private charitable, private non-cha	6

# 2. Staff employed in internal R&D activities in 2009

# 2.1 Staff employed in internal R&D, according to occupation

The full-time equivalent (FTE) is the sum of the staff that works full-time and the fractions of time that the part-time staff works on R&D activities. (See annex at the end of the questionnaire).

Occupation	Total	Women	Total on FTE * (1 decimal)	Women on FTE * (1 decimal)
1. Researchers (including interns in research)				<u> </u>
2. Technicians			<u> </u>	<u> </u>
3. Assistants			<u> </u>	<u> </u>
TOTAL STAFF (1+2+3)				. <u> </u>
Out of the researchers from point 1, please indicate the interns in			_	

2.2 Staff employed in internal R&D, according to qualification

	Staff in	R&D		Resear	chers (includ	ding interns)
Qualification	Total	Women	Total on FTE * (1 decimal)	Total	Women	Total on FTE (1 decimal)
1. University doctorate-holders				· -		
2. University graduates, architects, engineers and the like						
3. Diploma students, technical architects and						
engineers and the like				· -		
4. Advanced training cycles (Specific						
Vocational Training)						
5. Intermediate training cycles, Post-Secondary qualification						
and the like						
6. Other studies						
TOTAL (1+2+3+4+5+6)						

# 2.3 Distribution of staff in internal R&D, by Autonomous Cities and Communities in which the organisation or centre carries out R&D activities

	Staff in	R&D			Researc	hers (inclu	ding interns)	)
Autonomous Cities and Communities	Total	Women	Total on FTE * (1 decimal)	Women on FTE* (1 decimal)	Total	Women	Total on FTE * (1 decimal)	Women on FTE* (1 decimal)
1. Andalucía								
2. Aragón								
3. Asturias (Principado de)								
4. Balears (Illes)			. <u> </u>		_			
5. Canarias			. <u> </u>		_			
					_			
7 Castilla v. Lada								
8. Castilla-La Mancha			. <u> </u>					<u> </u>
9. Cataluña								<u> </u>
10. Comunitat Valenciana								<u> </u>
11. Extremadura								
12. Galicia								
13. Madrid (Comunidad de)								<u> </u>
14. Murcia (Región de)								. <u> </u>
15.Navarra (Comunidad Foral de)	-		<u> </u>					
16. País Vasco	-	_	. <u> </u>		_			
17. Rioja (La)	-	_	. <u> </u>		_			
18. Ceuta			. <u> </u>					
19. Melilla			. <u> </u>					
TOTAL			. <u> </u>		_			
(V) === = U								

2.4 Researchers, by sex and age grou	All ages	Under 25 years of age	25 to 34	35 to 44 years old	45 to 54 years old	55 to 64 years old	65 years old or over
Total researchers							
Of them, women							
2.5 Researchers, by nationality and s	ex (includ	ding interns	in resear	ch)			
	Oze (iiioia)	anig interne		Total rese	archers	Of them	n, women
Spain							
Rest of the EU <sup>1</sup>							
Other European countries							
North America							
Central America							
South America						<u> </u>	
Asia							
Africa							
Oceania							
TOTAL							
<sup>1</sup> Rest of the European Union: Germany, Austria, Belg	gium, Bulgari	a, Cyprus, Denm	ark, Slovakia,	, Slovenia, Esto	nia, Finland, Fr	ance, Greece,	Hungary, Ireland
Italy, Latvia, Lithuania, Luxembourg, Malta, Norway,	the Netherlar	nds, Poland, Port	ugal, the Unit	ed Kingdom, th	e Czech Repub	lic, Romania aı	nd Sweden.
2.6 Staff dedicated to internal R&D a	ctivities, l	by scientific	field or d	iscipline			
		Sta	ff in R&D		Researc	hers (includi	ng interns)
		Tot	al	Women	Total		Women
1. Exact and natural sciences							
2. Engineering and technology							
3. Medical sciences							
4. Agrarian							
5. Social sciences							
6. Humanities							
TOTAL				-			
3. Expenditure on R&D activit	ies in 2	009					
3.1 Expenditure on internal R&D acti	vities in 2	009					
Expenditure on remunerations shall be t technicians and assistants on FTE specified percentage of the part that corresponds to F	hose corre I in 2.1. For	sponding to					
						nount (ei imals)	uros withou
- Remunerations of researchers on FTE (inc	luding the r	emuneration	of interns)		1		
- Remunerations of technicians and assistar	nts				2		
- Other current expenses (without VAT or an	mortization	s)			3		
A. Total current expenditure on R&D					A		
- Equipment and instruments					4		
- Land and buildings (without VAT)					5		
- Acquisition of specific software for R&D (in	ncluding lic	ences) (witho	ut VAT)		6		
B Total capital expenditure on R&D							
C. Total internal expenditure on R&D					С		

# 3.2 Financing of internal R&D expenditure in 2009

Breakdown of the total internal expenditure on R&D from question 3.1, according to the original source of the funds received for R&D. In section B. Public financing should differentiate between the origin of funds, by type of Financing Administration, including within it the budgetary resources of the organisation, subsidies, loans, contracts, etc., according to the type of administration on which it depends.

without

(euros

Amount

Source of the funds		decimals)		
A. Financed by the actual organisation or centre				
- (This includes patrimonial income, refundable loans and income from sales or provision of services)	_1			
B. Public financing				
- From the State Administration and its Autonomous Institutions (AI)	1			
- From the State Administration to which it belongs (where appropriate) and its Al	2			
- From other Autonomous Administrations and their Al	3			
- From local administrations	4			
C. Other domestic sources to carry out R&D				
- From public companies	1			
- From private companies and research associations	2	-		
- From public universities	3	-		
- From private universities	4			_
- Private Non-Profit Institutions	5			_
D. Funds from abroad for carrying out R&D				
- From foreign companies	1			
- From the European Union	2			
- From foreign public administrations	3			_
- From foreign universities	4			
- From foreign Private Non-Profit Institutions	5			_
- From other international organisations	6			_
Total internal expenditure on R&D (this must coincide				_
3.3 Regionalization of internal R&D expenditure in 2009				
Please distribute the total internal expenditure on R&D indicated in question 3.1, according	to the A	utonomous	Commu	ınities
in which the R&D activities have been carried out.				
Autonomous Community		Amount decimals)	(euros	without
1. Andalucía	1			
2. Aragón	2			_
3. Asturias (Principado de)	3			_
4. Balears (Illes)	4			_
5. Canarias	5			_
6. Cantabria	6			_
7. Castilla y León	7			_
8. Castilla-La Mancha	8			
9. Cataluña	9			
10. Comunitat Valenciana	10			
11. Extremadura	11			
12. Galicia	12			
13. Madrid (Comunidad de)	13			
14. Murcia (Región de)	14			
15. Navarra (Comunidad Foral de)	15			
16. País Vasco	16			
17. Rioja (La)	17			
18. Ceuta	18			
19. Melilla	19			
Total internal expenditure on R&D (this must coincide				

### 3.4 Socio-economic objective Please break down, as a percentage, the expenditure on R&D that the organisation or centre has incurred in 2009, according to the socio-economic purpose or objective of the research (do not write decimals), and check that the sum of the percentages is 100%. % 1. Exploration and exploitation of the land media and of the atmosphere 1 2. Control and care of the environment % 3. Exploration and exploitation of space % 4.1 Transport and telecommunications systems % 4 1 4.2 Other infrastructures 4.2 % 5. Production, distribution and rational use of energy 5 % 6. Industrial production and technology 6 % 7 % 7. Protection and improvement of human health 8 8. Development of agriculture, livestock breeding, forestry and fishing % 9 % 10. Culture, leisure, religion and communication 10 % 11. Political and social systems, structures and processes 11 % % 12. Unguided research 12 13. Defence 13 % % TOTAL n 3.5 Research expenditure on the protection and improvement of human health If in the previous question (3.4 Socio-economic objective) there is a percentage of expenditure on R&D in point 7. Protection and improvement of human health, please indicate the expenditure, according to the Autonomous Cities and Communities in which the health research is carried out. (The percentage from point 7. Protection and improvement of human health, multiplied by the total research expenditure of the centre, must be equal to the expenditure on research in the protection and improvement of human health) **Autonomous Community** Amount decimals) 1. Andalucía 2 Aragón 3. Asturias (Principado de) 4. Balears (Illes) 5. Canarias 6. Cantabria 7. Castilla v León 8. Castilla-La Mancha 9. Cataluña 10. Comunitat Valenciana 11. Extremadura 12. Galicia 13. Madrid (Comunidad de) 14. Murcia (Región de) 15. Navarra (Comunidad Foral de) 16. País Vasco 17. Rioja (La) 18. Ceuta 19 Melilla Total expenditure on research in the protection and improvement of human health

# Please estimate the total value of the grants received in the year 2009 by the research interns listed in section 2.1, irregardless of the type of grant and the organisation that has granted it to them. This figure must be included in the remuneration of researchers from question 3.1. Amount (euros without decimals) 1. Research grants

3.7 Type of research

(\*) FTE: Full time equivalent

Please break down, as a percentage, the CURRENT internal expenditure on R&D that the organisation or centre	) ha	s ir	ncu	rred	in
2009, according to the following classification (do not write decimals, and check that the sum of the column is 10	ე%).				
1. Fundamental or basic research	1				%

2. Applied research							2			%
3. Experimental res							3		i i	_   %
Γ <b>OTAL</b>								1	0 0	
								•	•   •	
8.8 Activities bas	sed on biologic	cal sciences	and tec	hnologies	in 2009					
					to living organisms,	, as well as to th	eir parts, produ	icts a	nd mo	dels,
order to al	lter living or inert n	naterial, for the	purpose of	producing kr	nowledge, goods an	nd/or services.				
. Does the centre car or compounds obtains including biocomputi	ed from them, for tl	he purpose of o				ms YES N	IO → Plea	•	to sed 8.9	tion
. Indicate the resourc	es dedicated to act	tivities based or	biological	sciences and	technologies					
he full-time equivale piological sciences and		of the staff tha	works full	-time and the	fractions of time th	nat the part-time	staff works on	activ	rities b	ased (
	Personnel			Staff on FT	TE (1 decimal)	Total ex	penses (euros	with	no de	cimals
	Total	Women	_	Total	Women					
Resources used:				,						
3.9 Evolution of	the annual res	sources in s	cientific	research a	and technologi  Total staff on FT		ment activit Total interi R&D (euro	nal e	•	ture
Resources anticipa	ted for the year 2	2010								
Resources anticipa  (*) FTE: Full-time equiv		2010				<u>.</u>				
(*) FTE: Full-time equiv	alent.		rvices i	n 2009						
(*) FTE: Full-time equiv 3.10 Purchas This is caused by the	valent.  Se of externate acquisition of R&I	al R&D se	le of the org	ganisation or o			it does not inclu	de in	stitutio	nal
(*) FTE: Full-time equiv	valent.  Se of externate acquisition of R&I	al R&D se	le of the org	ganisation or o			Amount		stitutio	nal w
*) FTE: Full-time equiv  3.10 Purchas  This is caused by the quotas for financing	e acquisition of R&I other public or priv	al R&D services outsiderate organisation	le of the org	ganisation or o						
*) FTE: Full-time equiv 3.10 Purchas This is caused by the	e acquisition of R&I other public or priv	al R&D services outsiderate organisation	le of the org	ganisation or o			Amount			
3.10 Purchas This is caused by the quotas for financing  A. Purchase of R8 - From companies - From Public Adm	e acquisition of R&I other public or priv	D services outside at a representation of the services outside at a representation of the services of the serv	le of the org	ganisation or o		. '	Amount decimals)			
*) FTE: Full-time equiv  3.10 Purchas  This is caused by the quotas for financing  A. Purchase of R8 - From companies - From Public Adm - From universitie	e acquisition of R&I other public or priv	D services outside at a representation of the services outside at a representation of the services of the serv	le of the org	ganisation or o		. '	Amount decimals)  1 2 3			
3.10 Purchas 3.10 Purchas This is caused by the quotas for financing  A. Purchase of R8 - From companies - From Public Adn - From universitie - From Private No	calent.  Se of externa cacquisition of R&I other public or priv  AD services in Sp s ministration bodi s n-Profit Institution	al R&D se D services outsic rate organisation pain (without these	de of the orş	ganisation or o		. '	Amount decimals)			
3.10 Purchas 3.10 Purchas This is caused by the quotas for financing  A. Purchase of R8 - From companies - From Public Adn - From universitie - From Private No B. Purchase of R8	calent.  Se of externa cacquisition of R&I other public or priv  AD services in Sp s ministration bodi ss n-Profit Institution D services abroa	al R&D se D services outsic rate organisation pain (without these	de of the orş	ganisation or o		. '	Amount decimals)  1 2 3			
3.10 Purchas This is caused by the quotas for financing  A. Purchase of R8 - From companies - From Public Adn - From universitie - From Private No B. Purchase of R8 - From foreign companies	calent.  Se of externa cacquisition of R&I other public or priv  AD services in Sp s ministration bodi ss n-Profit Institution D services abroampanies	D services outsiderate organisation without the services of the services outsiderate organisation without the services of the	de of the orş	ganisation or o			Amount decimals)  1 2 3 4			
(*) FTE: Full-time equiv  3.10 Purchas  This is caused by the quotas for financing  A. Purchase of R8 - From companies - From Public Adn - From universitie - From Private No  B. Purchase of R8	calent.  Se of externa cacquisition of R&I other public or priv  AD services in Sp s ministration bodi s n-Profit Institution AD services abroa mpanies blic administration	D services outsiderate organisation without the services of the services outsiderate organisation without the services of the	de of the orş	ganisation or o			Amount decimals)  1 2 3			
(*) FTE: Full-time equiv  3.10 Purchas  This is caused by the quotas for financing  A. Purchase of R8 - From companies - From Public Adn - From universitie - From Private No  B. Purchase of R8 - From foreign colling	calent.  Se of externa cacquisition of R&I other public or priv  AD services in Sp s ministration bodi s n-Profit Institution AD services abroa mpanies blic administration iversities	al R&D seed as services outside attention of the services outside attention of the services outside attention of the services	de of the orş	ganisation or o			Amount decimals)  1 2 3 4 1 2			
*) FTE: Full-time equiv  3.10 Purchas  This is caused by the quotas for financing  A. Purchase of R8 - From companies - From Public Adn - From universitie - From Private No  B. Purchase of R8 - From foreign colling for the public purchase of R8 - From foreign purchase of prom foreign purchase of prom foreign university	calent.  Se of externa cacquisition of R&I other public or priv  AD services in Sp ministration bodi cs n-Profit Institution AD services abroa mpanies blic administration iversities ivate Non-Profit I	pain (without to cons descriptions descripti	de of the orş	ganisation or o			Amount decimals)  1 2 3 4 1 2 3 3			
*) FTE: Full-time equiv  3.10 Purchas  This is caused by the quotas for financing  A. Purchase of R8 - From companies - From Public Adn - From universitie - From Private No  B. Purchase of R8 - From foreign colling - From foreign pu - From foreign un - From foreign Private No	calent.  Se of externation of R&I other public or privaction of R&I other public of Services abroampanies blic administration iversities vate Non-Profit I rnational organis	pain (without vessel without vessel without vessel	de of the orş	ganisation or o			Amount decimals)  1 2 3 4 1 2 3 4			
3.10 Purchas 3.10 Purchas This is caused by the quotas for financing  A. Purchase of R8 From companies From Public Adn From universitie From Private No B. Purchase of R8 From foreign con From foreign pu From foreign un From foreign Pri From other inter C. Total purchase	calent.  Se of externa cacquisition of R&I other public or priv  AD services in Sp s ministration bodi s n-Profit Institution AD services abroa mpanies blic administration iversities ivate Non-Profit I rnational organis of R&D services	pain (without vestions distributions distrib	de of the orş s,,not im VAT)  xes)	ganisation or o	et purchase of R&D.		Amount decimals)  1 2 3 4 1 2 3 4			
3.10 Purchas 3.10 Purchas This is caused by the quotas for financing  A. Purchase of R8 From companies From Public Adn From universitie From Private No B. Purchase of R8 From foreign con From foreign pu From foreign pu From foreign un From other inter C. Total purchase  4. How long (	calent.  Se of external cacquisition of R&I other public or priv  AD services in Sp s in-Profit Institution cap services abroa mpanies blic administration iversities ivate Non-Profit I rnational organis of R&D services  did it take t	pair (without ves	de of the orse,, not im	ganisation or on a polying a direction of the direction of the polying a direction of the direction of the direction of the direction of the direction of th	nnaire?		Amount decimals)  1 2 3 4 1 2 3 4			
(*) FTE: Full-time equiv  3.10 Purchas  This is caused by the quotas for financing  A. Purchase of R8 - From companies - From Public Adn - From universitie - From Private No  B. Purchase of R8 - From foreign collision - From foreign pular - From foreign un - From foreign Pri - From other inter	calent.  Se of external cacquisition of R&I other public or priv  AD services in Sp s in-Profit Institution cap services abroa mpanies blic administration iversities ivate Non-Profit I rnational organis of R&D services  did it take t	pair (without ves	de of the orse,, not im	ganisation or on a polying a direction of the direction of the polying a direction of the direction of the direction of the direction of the direction of th	nnaire?		Amount decimals)  1 2 3 4 1 2 3 4	(6		
3.10 Purchas This is caused by the quotas for financing  A. Purchase of R8 From companies From Public Adn From universitie From Private No B. Purchase of R8 From foreign con From foreign pu From foreign un From foreign Pri From other inter C. Total purchase	calent.  Se of externa cacquisition of R&I other public or priv  AD services in Sp ministration bodi sc n-Profit Institution AD services abroa mpanies blic administration iversities ivate Non-Profit I rnational organis of R&D services  did it take to	pair (without ves	de of the orse,, not im	ganisation or on a polying a direction of the direction of the polying a direction of the direction of the direction of the direction of the direction of th	nnaire?		Amount decimals)  1	(6		

The National Statistics Institute would like to thank you for your cooperation

# 1 Scientific Research and Experimental Development (R&D) Activities

# 1.1 Basic definitions

Scientific research and experimental development (R&D) is comprised of the creative work carried out systematically in order to increase the volume of knowledge, including the knowledge of man, culture and society, and the use of this knowledge to create new applications.

The criterion referring to creative work carried out systematically is met by projects with specific objectives and a budget.

The term R&D comprises three activities: basic research, applied research and experimental development:

- Basic research consists of experimental or theoretical work that is mainly undertaken to obtain new knowledge on the essentials of observable phenomena and facts, without considering giving them any particular application or use whatsoever.
- Applied research also consists of the original work carried out to acquire new knowledge; however, it is mainly directed towards a specific practical objective.
- •Experimental development consists of systematic work based on existing knowledge, obtained from the research and/or practical experience, aimed at the production of new materials, products or devices; at the establishment of new processes, systems and services, or at the substantial improvement of those already existing.

A **criterion** that allows R&D to be distinguished from other related activities is the existence, within the core of R&D, of an appreciable element of innovation and the resolution of a scientific and/or technological uncertainty; in other words, R&D appears when the solution to a problem is not evident to someone who is perfectly aware of the set of knowledge and basic techniques customarily used in the sector at hand.

**Not constituting R&D** are those activities that do not contain an appreciable element of innovation, as well as those routine activities that do not imply the resolution of a scientific or technological uncertainty.

# 1.2 Staff in R&D

All staff directly employed in R&D must be accounted for. as well as those persons who provide services directly related to R&D activities, such as directors, administrators and office staff.

Researchers are professionals who work on the conception or creation of new knowledge, products, processes, methods and systems, and on the management of their respective projects (it includes postgraduate students and interns who carry out R&D activities).

**Technicians** and/or similar personnel are persons whose main tasks require technical knowledge and experience in one or various fields of engineering, physical and life sciences, or social sciences and humanities. They participate in R&D, carrying out scientific and technical tasks that require the application of operational methods and principles, generally under the supervision of researchers.

Assistants (remaining staff) include workers, both qualified and unqualified, and secretaries and office staff, who participate in the execution of the R&D projects, or who are directly related to the execution of said projects.

# 1.3 Staff in R&D on FTE

The staff on full-time equivalent (FTE) is the sum of the staff that works full-time and the fractions of time that the part-time staff works on R&D activities. Therefore, a person dedicated full-time to R&D shall be counted as 1, and a person who dedicates 20% of their time to R&D

shall be counted as 0.2. If someone works for three months full-time during the year, s/he will be counted as 0.25, as this is a quarter of the year. If a person works for part of the year full-time, and part of the year part-time, an estimation of the annual dedication to R&D will be calculated with a weighting (if s/he is, for example, 3 months full-time and 9 months 20% dedicated to R&D, then we calculate: 0.25\*1 + 0.75\*0.2 = 0.4).

# 1.4 Health research

This refers not only to biomedical research, but also to a broader field that includes R&D as regards health in the social sciences, above all, research in health services, intended to protect and promote human health

The medical sciences include the following scientific fields:

- Basic medicine (anatomy, cytology, physiology, genetics, pharmacy, pharmacology, toxicology, immunology and immuno-haematology, clinical chemistry, clinical microbiology, pathology)
- Clinical medicine (anaesthesia, paediatrics, obstetrics and gynaecology, internal medicine, surgery, odontology, neurology, psychiatry, radiology, therapy, otorhinolaryngology, ophthalmology)
- Health sciences (public health, social medicine, hygiene, nursing, pathology)

# **Examples of R&D in health**

- Research carried out in the fields of **medical sciences** (basic medicine, clinical medicine and health sciences). For example, research in cardiology, respiratory diseases, mental illness, etc.
- There is health research into **biological sciences**, particularly into genetics, the objective of which is human health. For example, cancer research, research into degenerative illnesses, etc.
- -Research into **social and humanitarian sciences**, the objective of which is to protect and improve human health. For example, research into prevention of drug addition
- The research into health and safety in nuclear power stations
- The autopsy carried out in order to study a specific case of mortality, for the purpose of establishing the side effects of a certain cancer treatment. A routine autopsy carried out in order to ascertain the causes of a particular death, responds to current medical practice, and is not considered research
- Clinical trials:

Prior to releasing new medications, vaccinations or treatments on the market, they must be subjected to systematic trials on human volunteers, in order to ensure that they are safe and effective. These clinical trials are divided into four standardised phases, three of which are carried out before permission to manufacture is granted. In order to be able to draw international comparisons, it has been agreed that phases 1, 2 and 3 may be included in R&D. Phase 4 of the clinical trials, in which the medicine or treatment undergoes continued trials following approval and manufacture, must only be included as R&D if it gives rise to scientific or technological advances. Moreover, not all activities carried out before obtaining permission to manufacture are considered R&D, especially when a significant lag in time occurs after finishing phase 3 of the trials, during which marketing and development activities may begin.

# 1 Scientific Research and Experimental Development (R&D) Activities

# 1.1 Basic definitions

Scientific research and experimental development (R&D) is comprised of the creative work carried out systematically in order to increase the volume of knowledge, including the knowledge of man, culture and society, and the use of this knowledge to create new applications.

The criterion referring to creative work carried out systematically is met by projects with specific objectives and a budget.

The term R&D comprises three activities: basic research, applied research and experimental development:

- Basic research consists of experimental or theoretical work that is mainly undertaken to obtain new knowledge on the essentials of observable phenomena and facts, without considering giving them any particular application or use whatsoever.
- Applied research also consists of the original work carried out to acquire new knowledge; however, it is mainly directed towards a specific practical objective.
- •Experimental development consists of systematic work based on existing knowledge, obtained from the research and/or practical experience, aimed at the production of new materials, products or devices; at the establishment of new processes, systems and services, or at the substantial improvement of those already existing.

A **criterion** that allows R&D to be distinguished from other related activities is the existence, within the core of R&D, of an appreciable element of innovation and the resolution of a scientific and/or technological uncertainty; in other words, R&D appears when the solution to a problem is not evident to someone who is perfectly aware of the set of knowledge and basic techniques customarily used in the sector at hand.

**Not constituting R&D** are those activities that do not contain an appreciable element of innovation, as well as those routine activities that do not imply the resolution of a scientific or technological uncertainty.

# 1.2 Staff in R&D

All staff directly employed in R&D must be accounted for. as well as those persons who provide services directly related to R&D activities, such as directors, administrators and office staff.

Researchers are professionals who work on the conception or creation of new knowledge, products, processes, methods and systems, and on the management of their respective projects (it includes postgraduate students and interns who carry out R&D activities).

**Technicians** and/or similar personnel are persons whose main tasks require technical knowledge and experience in one or various fields of engineering, physical and life sciences, or social sciences and humanities. They participate in R&D, carrying out scientific and technical tasks that require the application of operational methods and principles, generally under the supervision of researchers.

Assistants (remaining staff) include workers, both qualified and unqualified, and secretaries and office staff, who participate in the execution of the R&D projects, or who are directly related to the execution of said projects.

# 1.3 Staff in R&D on FTE

The staff on full-time equivalent (FTE) is the sum of the staff that works full-time and the fractions of time that the part-time staff works on R&D activities. Therefore, a person dedicated full-time to R&D shall be counted as 1, and a person who dedicates 20% of their time to R&D

shall be counted as 0.2. If someone works for three months full-time during the year, s/he will be counted as 0.25, as this is a quarter of the year. If a person works for part of the year full-time, and part of the year part-time, an estimation of the annual dedication to R&D will be calculated with a weighting (if s/he is, for example, 3 months full-time and 9 months 20% dedicated to R&D, then we calculate: 0.25\*1 + 0.75\*0.2 = 0.4).

# 1.4 Health research

This refers not only to biomedical research, but also to a broader field that includes R&D as regards health in the social sciences, above all, research in health services, intended to protect and promote human health

The medical sciences include the following scientific fields:

- Basic medicine (anatomy, cytology, physiology, genetics, pharmacy, pharmacology, toxicology, immunology and immuno-haematology, clinical chemistry, clinical microbiology, pathology)
- Clinical medicine (anaesthesia, paediatrics, obstetrics and gynaecology, internal medicine, surgery, odontology, neurology, psychiatry, radiology, therapy, otorhinolaryngology, ophthalmology)
- Health sciences (public health, social medicine, hygiene, nursing, pathology)

# **Examples of R&D in health**

- Research carried out in the fields of **medical sciences** (basic medicine, clinical medicine and health sciences). For example, research in cardiology, respiratory diseases, mental illness, etc.
- There is health research into **biological sciences**, particularly into genetics, the objective of which is human health. For example, cancer research, research into degenerative illnesses, etc.
- -Research into **social and humanitarian sciences**, the objective of which is to protect and improve human health. For example, research into prevention of drug addition
- The research into health and safety in nuclear power stations
- The autopsy carried out in order to study a specific case of mortality, for the purpose of establishing the side effects of a certain cancer treatment. A routine autopsy carried out in order to ascertain the causes of a particular death, responds to current medical practice, and is not considered research
- Clinical trials:

Prior to releasing new medications, vaccinations or treatments on the market, they must be subjected to systematic trials on human volunteers, in order to ensure that they are safe and effective. These clinical trials are divided into four standardised phases, three of which are carried out before permission to manufacture is granted. In order to be able to draw international comparisons, it has been agreed that phases 1, 2 and 3 may be included in R&D. Phase 4 of the clinical trials, in which the medicine or treatment undergoes continued trials following approval and manufacture, must only be included as R&D if it gives rise to scientific or technological advances. Moreover, not all activities carried out before obtaining permission to manufacture are considered R&D, especially when a significant lag in time occurs after finishing phase 3 of the trials, during which marketing and development activities may begin.